Hazlett Burt & Watson Inc. Acquires 1,569 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Hazlett Burt & Watson Inc. grew its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 156.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,569 shares of the biopharmaceutical company’s stock after acquiring an additional 1,569 shares during the period. Hazlett Burt & Watson Inc.’s holdings in Amicus Therapeutics were worth $28,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of FOLD. Assenagon Asset Management S.A. bought a new position in Amicus Therapeutics in the 2nd quarter worth $8,386,000. M&G Plc boosted its holdings in Amicus Therapeutics by 12.4% in the 2nd quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock worth $7,485,000 after buying an additional 82,728 shares during the period. Edgestream Partners L.P. boosted its holdings in Amicus Therapeutics by 1,290.4% in the 1st quarter. Edgestream Partners L.P. now owns 270,164 shares of the biopharmaceutical company’s stock worth $3,183,000 after buying an additional 250,734 shares during the period. CANADA LIFE ASSURANCE Co boosted its holdings in Amicus Therapeutics by 7.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock worth $1,183,000 after buying an additional 7,304 shares during the period. Finally, Fiera Capital Corp boosted its holdings in Amicus Therapeutics by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock worth $52,382,000 after buying an additional 58,113 shares during the period.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD opened at $11.33 on Tuesday. The firm’s 50-day moving average price is $11.15 and its 200-day moving average price is $10.59. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). The firm had revenue of $126.67 million for the quarter, compared to analysts’ expectations of $121.21 million. Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The business’s revenue was up 34.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.15) EPS. On average, equities research analysts expect that Amicus Therapeutics, Inc. will post -0.06 EPS for the current year.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total value of $79,500.00. Following the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $9,398,532.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 22,500 shares of company stock valued at $253,275 in the last ninety days. 2.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on FOLD. Morgan Stanley dropped their target price on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Friday, October 11th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 31st. JPMorgan Chase & Co. dropped their price objective on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 16th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price objective on shares of Amicus Therapeutics in a report on Friday, September 20th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Amicus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $17.13.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.